CXCL12 and non-small cell lung carcinoma: As CXCR4 expression increases with stage progression in NSCLC, targeting the CXCL12/CXCR4 axis in immunotherapy has also emerged as a treatment approach, though this axis is not prognostic in early-stage NSCLC patients of either sex [24,25].